packerfan9
2 semanas hace
8.5 billion new shares to be issued. I told people they never stop diluting and the buyback was a lie. Every day shares sold is dilution and that never changes. This will be at .0001 even sooner to sell all these.
CBD Life Sciences, Inc.
8,400,000,000 Shares of Common Stock
This Post-Qualification Offering Circular Amendment No. 3 amends the Offering Circular of CBD Life Sciences, Inc., a Nevada corporation (the “Company”), dated June 24, 2024, as qualified on June 21, 2024, and Post-Qualification Amendment No. 2 as filed on September 6, 2024, as qualified on September 17, 2024, and as may be amended and supplemented from time to time, to: (a) extend the expiration date of this offering to February 28, 2026; (b) to add 3,900,000,000 additional shares of common stock to the offered by this Offering Circular, for a revised maximum of 8,400,000,000 shares (collectively, the “Offered Shares”); and (c) to revise the offering price of the 6,687,062,556 shares of Company common stock that remain unsold (the “Remaining Shares”) to $__[0.0001-0.0006].
By this Offering Circular, the Company is offering for sale a maximum of 8,500,000,000 shares of its common stock (the Offered Shares), of which 1,478,666,729 shares have been sold for cash in the total amount of $696,310 and of which 6,687,062,556 shares, the Remaining Shares, at a fixed price of $__[0.0001-0.0006] per share, pursuant to Tier 1 of Regulation A of the United States Securities and Exchange Commission (the “SEC”). A minimum purchase of $5,000 of the Offered Shares is required in this offering; any additional purchase must be in an amount of at least $1,000. This offering is being conducted on a best-efforts basis, which means that there is no minimum number of Offered Shares that must be sold by us for this offering to close; thus, we may receive no or minimal proceeds from this offering. All proceeds from this offering will become immediately available to us and may be used as they are accepted. Purchasers of the Offered Shares will not be entitled to a refund and could lose their entire investments.
Chartmaster
3 semanas hace
BD Life Sciences Inc. (CBDL) Launches Mushroom Powder CapsulesPress Release | 02/26/2025
The Global Functional Mushroom Market is Set to Surpass $19 Billion by 2030—CBDL Enters the Booming Industry with Premium Mushroom Capsules for Cognitive Enhancement, Immune Support & Longevity!
SCOTTSDALE, ARIZONA / ACCESSWIRE / February 26, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is making a bold move into the multi-billion-dollar functional mushroom market with the official launch of its Mushroom Powder Capsules-a powerful, all-natural supplement designed to elevate brain function, enhance energy, boost immunity, and optimize overall wellness.
This premium formulation combines five of the most researched and revered medicinal mushrooms:
Lion's Mane - Known for its neuroprotective properties, enhances cognitive function, memory, and focus.
Cordyceps - Increases stamina, improves athletic performance, and supports lung function.
Reishi - Helps reduce stress, promotes better sleep, and strengthens the immune system.
Maitake - Supports metabolic health and helps regulate blood sugar levels.
Turkey Tail - Packed with antioxidants and polysaccharides that fortify gut health and boost immunity.
With scientific studies confirming the vast health benefits of these mushrooms, CBDL is positioning itself at the forefront of the natural health revolution. The global demand for functional mushrooms has skyrocketed due to their ability to combat stress, enhance brain power, and promote longevity-aligning perfectly with consumer trends toward holistic wellness and plant-based supplementation.
A Massive Revenue Opportunity
By launching into the functional mushroom industry, CBDL is tapping into a market projected to exceed $19 billion by 2030, with a CAGR of 9.1%. This strategic expansion will drive substantial new revenue streams and significantly increase consumer engagement with the brand.
CBDL's Mushroom Powder Capsules will be available through its existing sales channels, including direct-to-consumer e-commerce and select retail partners, with further distribution expansion planned as demand grows.
"This launch marks a pivotal moment for CBDL as we expand beyond CBD and into the booming functional mushroom sector," said Lisa Nelson, CEO of CBD Life Sciences Inc. "Our goal is to provide top-tier, science-backed natural solutions that enhance everyday health while capitalizing on one of the fastest-growing wellness trends in the world."
CBDL is committed to aggressive marketing, expanding its direct sales reach, and forming strategic partnerships to position its Mushroom Powder Capsules as a category leader. With consumer interest surging and scientific validation mounting, CBDL's foray into functional mushrooms represents not just an innovative product launch-but a major step toward long-term profitability and market dominance.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC:CBDL) is a leading innovator in the CBD and natural health industry, dedicated to developing high-quality, science-backed products that enhance wellness and vitality. With a growing portfolio spanning CBD topicals, edibles, and now functional mushrooms, CBDL continues to push boundaries in holistic health solutions.
For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Launches-Mushroom-Powder-Capsules?id=468863
AveragePenny
3 semanas hace
$CBDL CBD Life Sciences Inc. (CBDL) Launches Mushroom Powder Capsules
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/cbd-life-sciences-inc-cbdl-launches-mushroom-powder-capsules-991624
The Global Functional Mushroom Market is Set to Surpass $19 Billion by 2030—CBDL Enters the Booming Industry with Premium Mushroom Capsules for Cognitive Enhancement, Immune Support & Longevity!
SCOTTSDALE, ARIZONA / ACCESS Newswire / February 26, 2025 / CBD Life Sciences Inc. (OTC PINK:CBDL) is making a bold move into the multi-billion-dollar functional mushroom market with the official launch of its Mushroom Powder Capsules-a powerful, all-natural supplement designed to elevate brain function, enhance energy, boost immunity, and optimize overall wellness.
This premium formulation combines five of the most researched and revered medicinal mushrooms:
Lion's Mane - Known for its neuroprotective properties, enhances cognitive function, memory, and focus.
Cordyceps - Increases stamina, improves athletic performance, and supports lung function.
Reishi - Helps reduce stress, promotes better sleep, and strengthens the immune system.
Maitake - Supports metabolic health and helps regulate blood sugar levels.
Turkey Tail - Packed with antioxidants and polysaccharides that fortify gut health and boost immunity.
With scientific studies confirming the vast health benefits of these mushrooms, CBDL is positioning itself at the forefront of the natural health revolution. The global demand for functional mushrooms has skyrocketed due to their ability to combat stress, enhance brain power, and promote longevity-aligning perfectly with consumer trends toward holistic wellness and plant-based supplementation.
A Massive Revenue Opportunity
By launching into the functional mushroom industry, CBDL is tapping into a market projected to exceed $19 billion by 2030, with a CAGR of 9.1%. This strategic expansion will drive substantial new revenue streams and significantly increase consumer engagement with the brand.
CBDL's Mushroom Powder Capsules will be available through its existing sales channels, including direct-to-consumer e-commerce and select retail partners, with further distribution expansion planned as demand grows.
"This launch marks a pivotal moment for CBDL as we expand beyond CBD and into the booming functional mushroom sector," said Lisa Nelson, CEO of CBD Life Sciences Inc. "Our goal is to provide top-tier, science-backed natural solutions that enhance everyday health while capitalizing on one of the fastest-growing wellness trends in the world."
CBDL is committed to aggressive marketing, expanding its direct sales reach, and forming strategic partnerships to position its Mushroom Powder Capsules as a category leader. With consumer interest surging and scientific validation mounting, CBDL's foray into functional mushrooms represents not just an innovative product launch-but a major step toward long-term profitability and market dominance.
Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
RedSox04
3 semanas hace
Hot Features
Premium
